Herpes simplex virus and cytomegalovirus lung reactivations in severe COVID-19 patients: to treat or not to treat? That is (still) the question

Intensive Care Med. 2024 Aug;50(8):1317-1319. doi: 10.1007/s00134-024-07562-w. Epub 2024 Jul 24.
No abstract available

Publication types

  • Letter
  • Editorial

MeSH terms

  • Antiviral Agents / therapeutic use
  • COVID-19* / complications
  • COVID-19* / therapy
  • Cytomegalovirus
  • Cytomegalovirus Infections / complications
  • Cytomegalovirus Infections / drug therapy
  • Herpes Simplex* / complications
  • Herpes Simplex* / drug therapy
  • Humans
  • Lung / physiopathology
  • SARS-CoV-2
  • Simplexvirus / pathogenicity
  • Virus Activation

Substances

  • Antiviral Agents